



Pediatric Pulmonology: State-of-the-Art

# Hereditary Hemorrhagic Telangiectasia – What has changed since Osler, Weber and Rendu?

**Meir Mei-Zahav, MD**

Director, the National HHT Center and Asthma Service

Graub Cystic Fibrosis Center

Pulmonary Institute; Schneider Children's Medical Center of Israel

**Virtual via ZOOM**

**March 15, 2024**

**8:00-9:00 AM**

**To claim credit,  
text **VODCEW**  
to **703.260.9391****

**Target audience:** Pediatric Pulmonologists; Advance Practice Practitioners, nurses and respiratory therapists in pulmonary medicine; Intensivists; Emergency Medicine physicians; Allergists; General Pediatricians

**Learning objectives:**

- HHT is an autosomal dominant vascular dysplasia, more common than previously thought.
- HHT is a multi-organ disease and can present as a life-threatening event.
- Screening of HHT patients and family members for visceral AVMs can prevent these events.
- The risk of developing life-threatening events in childhood is not different from the risk in adulthood.

**Accreditation:** This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Medical Society of Virginia (MSV) through the joint providership of Inova Office of Continuing Medical Education and Children's National Medical Center. The Inova Office Continuing Medical Education is accredited by the Medical Society of Virginia to provide continuing education for physicians.

**Credit designation:** The Inova Office of Continuing Medical Education designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity. Physicians may claim up to 1.0 credit in Type 1 CME on the Virginia Board of Medicine Continued Competency and Assessment Form required for renewal of an active medical license in Virginia.

